Molecular mechanism of ensitrelvir inhibiting SARS-CoV-2 main protease and its variants
Molecular mechanism of ensitrelvir inhibiting SARS-CoV-2 main protease and its variants
About this item
Full title
Author / Creator
Publisher
London: Nature Publishing Group UK
Journal title
Language
English
Formats
Publication information
Publisher
London: Nature Publishing Group UK
Subjects
More information
Scope and Contents
Contents
SARS-CoV-2 poses an unprecedented threat to the world as the causative agent of the COVID-19 pandemic. Among a handful of therapeutics developed for the prevention and treatment of SARS-CoV-2 infection, ensitrelvir is the first noncovalent and nonpeptide oral inhibitor targeting the main protease (M
pro
) of SARS-CoV-2, which recently receive...
Alternative Titles
Full title
Molecular mechanism of ensitrelvir inhibiting SARS-CoV-2 main protease and its variants
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_doaj_primary_oai_doaj_org_article_c99a42094b8d4648bb74233b8cdf41f9
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_c99a42094b8d4648bb74233b8cdf41f9
Other Identifiers
ISSN
2399-3642
E-ISSN
2399-3642
DOI
10.1038/s42003-023-05071-y
